Key Documents
- FDA Inspection Report of Philips Respironics, Inc., November 9, 2021
- “Health risks related to polyurethane foam degradation in CPAP devices used for sleep apnea treatment”, European Respiratory Journal, February 4, 2022
- FDA Philips 518(a) Notification Order, March 10, 2022
- FDA Philips 518(b) Notice of Opportunity for a Hearing, May 2, 2022
- Email correspondences and affidavit of Lee Lawler, former Technical Director at Wm. T. Burnett & Co.’s Foam Division, about potential for degradation of foam in Philips devices
- Short Form Complaint (PDF, Word)
- PLEASE BE ADVISED when filing a new action in the MDL that Disclosure Statements (required by Fed.R.Cv.P 7.1 and LCvR 7.1) are waived for any party or intervenor appearing in MDL 3014, pursuant to the Court’s Order of 1/11/2023 (Doc. 1397). This applies to the master docket and the individual civil action dockets.
- Class Action Complaint For Economic Losses
- Class Action Complaint For Medical Monitoring
- Master Personal Injury Complaint